Sinovac Biotech Statistics Share Statistics Sinovac Biotech has 71.86M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 71.86M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 17.19M Failed to Deliver (FTD) Shares n/a FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 81.83K, so 0.11% of the outstanding
shares have been sold short.
Short Interest 81.83K Short % of Shares Out 0.11% Short % of Float 0.19% Short Ratio (days to cover) 999.99
Valuation Ratios The PE ratio is -6.45 and the forward
PE ratio is null.
Sinovac Biotech's PEG ratio is
0.03.
PE Ratio -6.45 Forward PE n/a PS Ratio 1.44 Forward PS n/a PB Ratio 0.07 P/FCF Ratio -15.46 PEG Ratio 0.03
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Sinovac Biotech.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 10.31,
with a Debt / Equity ratio of 0.03.
Current Ratio 10.31 Quick Ratio 10.18 Debt / Equity 0.03 Debt / EBITDA -49.59 Debt / FCF -7.17 Interest Coverage -241.91
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $228.83K Profits Per Employee $-51K Employee Count 1,959 Asset Turnover 0.03 Inventory Turnover 1.3
Taxes Income Tax 105.32M Effective Tax Rate -68.82%
Stock Price Statistics The stock price has increased by null% in the
last 52 weeks. The beta is 0, so Sinovac Biotech's
price volatility has been lower than the market average.
Beta 0 52-Week Price Change n/a 50-Day Moving Average 6.47 200-Day Moving Average n/a Relative Strength Index (RSI) 100 Average Volume (20 Days) n/a
Income Statement In the last 12 months, Sinovac Biotech had revenue of 448.27M
and earned -99.92M
in profits. Earnings per share was -1.06.
Revenue 448.27M Gross Profit 266.75M Operating Income -546.72M Net Income -99.92M EBITDA -6.03M EBIT -150.77M Earnings Per Share (EPS) -1.06
Full Income Statement Balance Sheet The company has 1.27B in cash and 298.98M in
debt, giving a net cash position of 971.15M.
Cash & Cash Equivalents 1.27B Total Debt 298.98M Net Cash 971.15M Retained Earnings 7.12B Total Assets 13.66B Working Capital 10.68B
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was 104M
and capital expenditures -145.69M, giving a free cash flow of -41.69M.
Operating Cash Flow 104M Capital Expenditures -145.69M Free Cash Flow -41.69M FCF Per Share -0.42
Full Cash Flow Statement Margins Gross margin is 59.51%, with operating and profit margins of -121.96% and -22.29%.
Gross Margin 59.51% Operating Margin -121.96% Pretax Margin -34.14% Profit Margin -22.29% EBITDA Margin -1.34% EBIT Margin -121.96% FCF Margin -9.3%
